Bausch Health Companies news

Strong Q2 earnings beat with 13% YoY revenue growth and 42% adjusted net income growth. Company raised full-year 2026 guidance for both revenue and adjusted EBITDA. Regulatory approval in Canada for Prokedi and 13 consecutive quarters of YoY growth demonstrate momentum across the diversified portfolio.

Company delivered earnings beats on both revenue ($2.52B vs $2.42B consensus) and non-GAAP EPS ($0.78 vs $0.68 consensus), with strong 12% revenue growth and 35% net income growth. Maintained full-year guidance and demonstrated 12 consecutive quarters of YoY revenue growth, resulting in stock appreciation of ~2% for the week.

Positioned as a key competitor in the dermatology devices market experiencing robust growth driven by demographic trends and technological innovation.

Markets CABTREO (clindamycin phosphate/adapalene/benzoyl peroxide), the first fixed-dose topical triple-combination therapy. Represents innovation in combination treatments targeting multiple acne pathogenic mechanisms.

Positioned as a major key player in the expanding body contouring devices market with favorable growth projections.

Recommended as defensive healthcare stock with 16.6% expected earnings growth and 7.4% improvement in consensus estimates over 60 days. Carries Zacks Rank #2 rating.

Company markets XIFAXAN, the only FDA-approved therapy specifically for hepatic encephalopathy. However, recent Phase III trial for amorphous-rifaximin failed to meet primary endpoint, indicating challenges in pipeline expansion despite current market leadership.

Bausch Health markets DEMSER (metyrosine), an established therapy approved since 1979. While it remains part of the treatment arsenal, it represents older standard-of-care therapy with limited growth potential as newer mechanism-driven therapies emerge.